| First Author | Desai AA | Year | 2021 |
| Journal | J Biol Chem | Volume | 296 |
| Pages | 100508 | PubMed ID | 33675750 |
| Mgi Jnum | J:311259 | Mgi Id | MGI:6695477 |
| Doi | 10.1016/j.jbc.2021.100508 | Citation | Desai AA, et al. (2021) Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity. J Biol Chem :100508 |
| abstractText | The aggregation of amyloidogenic polypeptides is strongly linked to several neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. Conformational antibodies that selectively recognize protein aggregates are leading therapeutic agents for selectively neutralizing toxic aggregates, diagnostic and imaging agents for detecting disease, and biomedical reagents for elucidating disease mechanisms. Despite their importance, it is challenging to generate high-quality conformational antibodies in a systematic and site-specific manner due to the properties of protein aggregates (hydrophobic, multivalent and heterogeneous) and limitations of immunization (uncontrolled antigen presentation and immunodominant linear epitopes). Toward addressing these challenges, we have developed a systematic directed evolution procedure for affinity maturing antibodies against Alzheimer's Abeta fibrils and selecting variants with strict conformational and sequence specificity. We first designed a library based on a lead conformational antibody by sampling combinations of amino acids in the antigen-binding site predicted to lead to high antibody specificity. Next, we displayed this library on the surface of yeast, sorted it against Abeta aggregates, and identified promising clones using deep sequencing. We identified several antibodies with similar or higher affinities than clinical-stage Abeta antibodies (aducanumab and crenezumab). Moreover, the affinity-matured antibodies retain high conformational specificity for Abeta aggregates, as observed for aducanumab and unlike crenezumab. Notably, the affinity-maturated antibodies display extremely low levels of non-specific interactions, as observed for crenezumab and unlike aducanumab. We expect that our systematic methods for generating antibodies with unique combinations of desirable properties will improve the generation of high-quality conformational antibodies specific for diverse types of aggregated conformers. |
